Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency disorders...
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

Overview
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Development of Immunocompetence01:22

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Review: Feeding strategies to meet the dynamic lysine and energy requirements of gestating and lactating sows.

Animal : an international journal of animal bioscience·2025
Same author

A comparative study of fetal cardiovascular assessment: utilizing Doppler ultrasound gated MRI and echocardiography with detailed analysis using five axial views.

Frontiers in cardiovascular medicine·2024
Same author

Blending gestation and lactation diets during the transition period reduces energy mobilization by sows in late gestation, with no impact on subsequent lactation performance.

Translational animal science·2024
Same author

[Outcome of ABO-incompatible living-donor kidney transplants : A plea for crossover living-donor kidney transplantation].

Urologie (Heidelberg, Germany)·2024
Same author

[Report on the 29th annual meeting of the kidney transplantation working group of the German Society of Urology in Marburg 2023].

Urologie (Heidelberg, Germany)·2024
Same author

Rare Case of Tularemia With Preauricular Lymphadenopathy and Conjunctivitis in a 27-Year-Old Male Patient in Germany.

Ear, nose, & throat journal·2024

Related Experiment Video

Updated: May 11, 2026

Murine Full-thickness Skin Transplantation
07:59

Murine Full-thickness Skin Transplantation

Published on: January 2, 2017

New perspectives of immunosuppression.

F Halleck1, F Friedersdorff, T F Fuller

  • 1Department of Nephrology, Charité Universitätsmedizin Berlin, Germany. fabian.halleck@charite.de

Transplantation Proceedings
|April 30, 2013
PubMed
Summary

New immunosuppressive drugs and strategies are needed to improve long-term organ transplant survival. Current treatments show limited long-term benefits, highlighting an unmet need for better immunosuppression with fewer side effects.

More Related Videos

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

Related Experiment Videos

Last Updated: May 11, 2026

Murine Full-thickness Skin Transplantation
07:59

Murine Full-thickness Skin Transplantation

Published on: January 2, 2017

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

Area of Science:

  • Immunology
  • Transplantation Medicine
  • Pharmacology

Background:

  • Long-term organ transplant survival remains suboptimal despite effective short-term rejection prophylaxis.
  • Graft attrition rates are constant beyond the first year post-transplant, indicating a persistent unmet medical need.
  • Current immunosuppressive regimens, primarily calcineurin inhibitor-based, have limitations in improving long-term patient and graft survival.

Purpose of the Study:

  • To review recent advancements in novel immunosuppressive drugs and strategies for organ transplantation.
  • To explore potential alternatives to current calcineurin inhibitor-based regimens.
  • To identify approaches that may improve long-term graft and patient survival with reduced side effects.

Main Methods:

  • Review of current literature on novel immunosuppressive agents and strategies.
  • Analysis of ongoing and planned clinical trials in renal transplant recipients.
  • Evaluation of emerging immunosuppressive regimens for efficacy and tolerability.

Main Results:

  • Several promising novel immunosuppressive drugs are under development.
  • New immunosuppressive strategies are emerging as potential alternatives to calcineurin inhibitors.
  • These novel approaches aim for comparable efficacy with improved tolerability or a different side-effect profile.

Conclusions:

  • There is a significant unmet need for improved long-term outcomes in organ transplantation.
  • Novel immunosuppressive drugs and strategies offer potential solutions to enhance graft and patient survival.
  • Future regimens may provide better tolerability and clinical benefits compared to existing treatments.